Rosiglitazone inhibits cell proliferation by inducing g1 cell cycle arrest and apoptosis in ADPKD cyst-lining epithelia cells

Basic and Clinical Pharmacology and Toxicology

Volumn 106, Issue 6, 2010, Pages 523-530

  Liu, Yawei ^a   Dai, Bing ^a   Fu, Lili ^a   Jia, Jieshuang ^a   Mei, Changlin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; CYCLIN D1; CYCLIN D2; CYCLIN DEPENDENT KINASE 4; CYCLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CORTEX; KIDNEY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; AGONISTS; CELL CULTURE; CELL LINE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; KIDNEY; METABOLISM; PATHOLOGY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; TIME;

APOPTOSIS; CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; G0 PHASE; G1 PHASE; HUMANS; KIDNEY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PPAR GAMMA; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 77952284479     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2010.00539.x     Document Type: Article

References (38)

1. Martinez JR, Grantham JJ. Polycystic kidney disease: etiology, pathogenesis, and treatment. Dis Mon 1995 41 : 693 765.
2. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007 369 : 1287 1301.
3. Sutters M, Germino GG. Autosomal dominant polycystic kidney disease:Molecular genetics and pathophysiology. J Lab Clin Med 2003 141 : 91 101.
4. Lanoix J, D'Agati V, Szabolcs M, Trudel M. Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD). Oncogene 1996 13 : 1153 1160. (Pubitemid 26343568)
5. Nadasdy T, Laszik Z, Lajoie G, Blick KE, Wheeler DE, Silva FG. Proliferative activity of cyst epithelium in human renal cystic diseases. J Am Soc Nephrol 1995 5 : 1462 1468.
6. Chang MY, Parker E, Ibrahim S, Shortland JR, Nahas ME, Haylor JL et al. Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models. Nephrol Dial Transplant 2006 21 : 2078 2084.
7. Woo DD, Miao SY, Pelayo JC, Woolf AS. Taxol inhibits progression of congenital polycystic kidney disease. Nature 1994 368 : 750 753.
8. Torres VE, Sweeney WE Jr., Wang X, Qian Q, Harris PC, Frost P et al. EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats. Kidney Int 2003 64 : 1573 1579.
9. Gattone VH 2nd., Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003 10 : 1323 1326.
10. Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005 16 : 46 51.
11. Bukanov NO, Smith LA, Klinger KW, Ledbetter SR, Ibraghimov-Beskrovnaya O. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 2006 444 : 949 952.
12. Omori S, Hida M, Fujita H, Takahashi H, Tanimura S, Kohno M et al. Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. J Am Soc Nephrol 2006 17 : 1604 1614.
13. Sweeney WE Jr., von Vigier RO, Frost P, Avner ED. Src inhibition ameliorates polycystic kidney disease. J Am Soc Nephrol 2008 19 : 1331 1341.
14. Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 1997 8 : 159 166.
15. Kliewer SA, Lehmann JM, Milburn MV, Willson TM. The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways. Recent Prog Horm Res 1999 54 : 345 367.
16. Palmer CN, Hsu MH, Griffin HJ, Johnson EF. Novel sequence determinants in peroxisome proliferator signaling. J Biol Chem 1995 270 : 16114 16121.
17. Chawla A, Schwarz E, Dimaculangan D, Lazar M. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994 135 : 798 800.
18. Spiegelman B. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998 47 : 507 514.
19. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 2004 5 : 419 429.
20. Mori Y, Hirano T, Nagashima M, Shiraishi Y, Fukui T, Adachi M. Decreased peroxisome proliferator-activated receptor alpha gene expression is associated with dyslipidemia in a rat model of chronic renal failure. Metabolism 2007 56 : 1714 1718.
21. Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, Doi T et al. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest 2009 89 : 47 58.
22. Inoue K, Kawahito Y, Tsubouchi Y, Kohno M, Yoshimura R, Yoshikawa T et al. Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem Biophys Res Commun 2001 287 : 727 732.
23. Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 2001 60 : 14 30.
24. Muto S, Aiba A, Saito Y, Nakao K, Nakamura K, Tomita K et al Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet 2002 11 : 1731 1742.
25. Xu CG, Mei CL, Zhang LM. Establishment and identification of ADPKD cyst-lining epithelia cell lines. J Nephrol Dial Transplant 2000 9 : 142 145.
26. Wang W, Mei C, Tang B, Zhao H, Xu C, Li Z et al. Aberrant expression of SPARC and its impact on proliferation and apoptosis in ADPKD cyst-lining epithelia. Nephrol Dial Transplant 2006 21 : 1278 1288.
27. Ferruzzi P, Ceni E, Tarocchi M, Grappone C, Milani S, Galli A et al. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab 2005 90 : 1332 1339.
28. Valentiner U, Carlsson M, Erttmann R, Hildebrandt H, Schumacher U. Ligands for the peroxisome proliferator-activated receptor-g have inhibitory effects on growth of human neuroblastoma cells in vitro. Toxicology 2005 213 : 157 158.
29. Yu HN, Lee YR, Noh EM, Lee KS, Kim JS, Song EK et al. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand. Cell Biol Int 2008 32 : 906 912.
30. He Q, Pang R, Song X, Chen J, Chen H, Chen B et al. Rosiglitazone suppresses the growth and invasiveness of SGC-7901 gastric cancer cells and angiogenesis in vitro via PPARgamma dependent and independent mechanisms. PPAR Res 2008 2008 : 649808.
31. Sheu WH, Ou HC, Chou FP, Lin TM, Yang CH. Rosiglitazone inhibits endothelial proliferation and angiogenesis. Life Sci 2006 78 : 1520 1528.
32. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclindependent kinase inhibitors (CKIs). Oncogene 1995 11 : 211 219.
33. Lees E. Cyclin dependent kinase regulation. Curr Opin Cell Biol 1995 7 : 773 780.
34. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995 9 : 1149 1163.
35. Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway in cell cycle control and cancer. Exp Cell Res 1997 237 : 1 6.
36. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995 81 : 323 330.
37. Zhang CL, Wu LJ, Tashiro S, Onodera S, Ikejima T. Oridonin induces apoptosis of HeLa cells via altering expression of Bcl-2/Bax and activating caspase-3/ICAD pathway. Acta Pharmacol Sin 2004 25 : 691 698.
38. Filippova M, Parkhurst L, Duerksen-Hughes PJ. The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-riggered apoptosis. J Biol Chem 2004 279 : 25729 25744.